Reddit Posts
Do y’all think the Autonomix (NASDAQ: AMIX) IPO tomorrow has the potential to be the TOP IPO of 2024?
EBYH - "We are thrilled to conclude 2023 with our most substantial orders to date".
If an acquisition is announced at $X/share, why would anyone sell it for LESS?!
Individual stocks vs ETF vs REIT vs Robo-investing
BNOX - Bionomics Shares In Rally Mode As Investors Take Interest Ahead Of Planned Phase III Trial To Treat PTSD And SAD ($BNOX)
$NRXS IBS treatment with less side effects than their competitors
Is having a money manager/"Private CFO" worth it?
What would you buy for a short-term medium risk profit expectation right now? Would you sell your most disappointing stock to buy that?
How do I decide between initating a new position vs adding to an existing one?
Looking for help on when to initiate a new position vs DCA an existing one?
Time to dump tech and buy dividend stocks?
Pharmaceuticals break COVID lows trend line signaling end to Bear Market
AbbVie down 7%. Humira sales down 25% As Biosimilars Hammer Away At Sales
AbbVie gains as Skyrizi succeeds in ulcerative colitis (NYSE:ABBV)
2023-02-27 Wrinkle-brain Plays (Mathematically derived options plays)
AbbVie sued in Netherlands for breaching human rights over Humira pricing (NYSE:ABBV)
Next big wave of patent cliffs ahead; expect biopharma M&A to rise (NYSE:ABBV)
$BIOR rising on short squeeze lists. Currently only $30M market cap... Imagine would it could be worth to ABBV as a way to regain patent protection on Humira... explains current $65 price target. Could run incredibly high...
The investor who bought 2.1 Million shares the last session is $7,035,000.00 wealthier in just 24 hours
My short, intermediate, &long and good divident stock reversal confirmed. Shortsqueeze and gamma squeeze (score 87) is a real possibility
AbbVie sets outlook below consensus amid generic threat to best selling drug (NYSE:ABBV)
AbbVie pins hopes on newer drugs and deals to face Humira knockoffs (NYSE:ABBV)
Drug price inflation continues upward momentum at 3.8% – report (NYSE:ABBV)
U.K. pharma lobby urges govt. to halt plans to raise revenue recovery rates (NYSE:ABBV)
AbbVie’s global bestseller Humira to face knockoffs this week (NYSE:ABBV)
My 2022 strategy been working well I guess ¯\_(ツ)_/¯
What are some good healthcare stocks to hold long-term?
Shorting ABBV: Machine Learning Model.
Looking for some constructive advice on my Roth portfolio. What would you cut to get this down to an even 10 stocks?
Why are people throwing money at TEVA after the recent Supreme Court ruling?
Birth control-related pharma plays $OGN $ABBV $TEVA $JNJ
Birth Control-related Pharma Plays $OGN $ABBV $TEVA $JNJ
What did you bought today? Just got some BMO and JPM pretty cheap myself!
$ABBV which trades at $140 has a stake in $XCUR which trades at 18 cents - they are partnered and its all confirmed in partners earnings call. I’ve been going through everything trying to figure out why this is so low and can’t rationalize it. Has .69 cash per share as well.
$XCUR - go through Ipsens Feb 2022 presentation - the partnership with $IPSEY is legit this was at $2 when it was announced. $ABBV must be legit as well:
$XCUR - go through Ipsens Feb 2022 presentation - the partnership with $IPSEY is legit this was at $2 when it was announced. $ABBV must be legit as well:
$XCUR it’s all fucking legit with $ABBV and $IPSEY cant believe it’s at .18 cents. It’s all confirmed on Ipsens earnings call four days ago.
Some big news on $XCUR in most recent $IPSEY Earnings Call they stated the partnerships are continuing. Which means $ABBV partnership still intact. This could be the $BNGO of this year running pennies to dollars.
If you only had to hold a few individual stocks, which would you choose? Or just throw everything in ETFs?
Fat bids on $XCUR all afternoon don’t think this is done. Maybe the partnership with $ABBV and $IPSEY are legit. They just have a shit CEO rn
Big picture on $XCUR is average cost is .80 and PTs range from .40-$6 I just think these prices won’t ever come back. Going long for better or worse but $ABBV partnership isn’t something that can be ignored the Chairman is the CEO of $HZNP
$XCUR - risky play but high risk high reward! The latest filing states the partnerships with ABBV and IPSEY are going fully ahead:
When Partnership news hits $XCUR it’s going straight to $1 at minimum. There’s no way these prices stay this low. When $ABBV announced it ran to $3.30 this could be the next $BNGO pennies to dollars imo
When Partnership news hits $XCUR it’s going straight to $1 at minimum. There’s no way these prices stay this low. When $ABBV announced it ran to $3.30
Partnership news is what will send $XCUR up im holding from .16 waiting til news hits. The partnerships with $ABBV and $IPSEY took it from .90-$3.30 we should have neuroscience partnership news soon worth $1.9B
Partnership news is what will send $XCUR up im holding from .16 waiting til news hits. The partnerships with $ABBV and $IPSEY took it from .90-$3.30 we should have neuroscience partnership news soon worth $1.9B
The major pharma partnerships with $ABBV and $IPSEY make $XCUR extremely undervalued. I can’t wrap head around it under $1 in all honesty. Sorry if keep posting and it’s turned spammy - go through all the DD and make mind up. In my mind it doesn’t make sense when partners were announced it was $3.50
$XCUR - I think it can get to $15 on successful execution of partnerships they have locked contracts with $ABBV (trades $140 and $IPSEY trades $24) worth 4 BILLION in revenue and are in the process of partnering Neuroscience and Pain side in early 2022. Institutions loaded at .33 off last offering:
$XCUR - I think it can get to $15 on successful execution of partnerships they have locked contracts with $ABBV (trades $140 and $IPSEY trades $24) worth 4 BILLION in revenue and are in the process of partnering Neuroscience and Pain side in early 2022. Institutions loaded at .33 off last offering:
$XCUR - I think it can get to $15 on successful execution of partnerships they have locked contracts with $ABBV (trades $140 and $IPSEY trades. $15) worth 4 BILLION in revenue and are in the process of partnering Neuroscience and Pain side in early 2022. Institutions loaded at .33 off last offering:
$XCUR it’s partners trades at $140!!! $ABBV and $IPSEY. The CEO of $HZNP which trades at $90 is chairman of $XCUR - i think this is the next $BNGO and could potentially run to $10 - these partnerships aren’t a joke.
There’s a shit ton of naked shorts in $XCUR is nobody seeing this PA this could really go like $BNGO from pennies to $10+ these are some insane partnerships with major major pharma $ABBV trades at $140
$XCUR is a $PROG 2.0 - some warrants were issued at .01 but they haven’t redeemed the .27 warrants or the shares at .33 per Jan 2022 filing which would push the price to .50 minimum on execution. The neuroscience and pain partner will be announced in 2022 - it did a 60% move on IPSEN and $ABBV news:
$XCUR (currently 16 cents) - $ABBV and $IPSEY 1B Partnership Breakdown:
When $XCUR first IPO’d they issued it a $9 PT the fact it’s 16 cents now is unbelievable with an $ABBV and $IPSEY partnership. If you’re able to buy 100k shares rn and sit for a year or two it’s an easy 5-10X money imo.
$XCUR - Partnered with $ABBV and $IPSEY - is this the next $BNGO type runner 🧐
$XCUR - Partnered with $ABBV and $IPSEY - is this the next $BNGO type runner 🧐
$XCUR - Partnered with $ABBV and $IPSEY - is this the next $BNGO type runner 🧐
$XCUR is very interesting down here partnered with $ABBV
How many of you use leverage or borrowed money to boost your portfolios?
Stocks you can’t wait to see dip because you’re itching to buy them
ABBV Valuation from $111 to $172...just like that huh?
ABBV Valuation from $111 to $172...just like that huh?
Buyout Coming Soon ABBV. Buy all you can, once in a Lifetime here
Earnings for this week & Next week (Me, ABBV, AMC, APPL, etc….)
Stock picks for a 10 year hold with the hope of 5x my money...which ones?
$ABBV short term calls Gain with more to come after Friday announcement with RGNX! Here we go!!!
Let's try $ABBV short term calls. Retina meeting this Friday. Data hopefully is good 10/8 high risk high reward calls. YOLO!
The Cutting Edge: $ATNF, $ABBV, and Adalimumab
Mentions
With Noem being replaced, puts on ABBV (owner of Botox)?
To many individual stocks...long term stick with maybe 10-15 individual stocks covering different industries like CAT, MSFT, CVX, ABBV, EMR, RTX, JPM, PG, GOOG, GLD, AMD etc...companies that have been successful for a long long time, pays dividends and when one sector is down another sector will be up, ride the waves ! Put some in a S&P Index Fund, a Dividends Index Fund just diversify and slowly add to each, time is your friend
Thank you for your comment. I provided context on this in another comment in the Part 1 post, but readding it here for anyone new: Here is an overview in a concise way: GPS annual sales will be at least $4B and GPS + SLS-009 will be $6.5B to $8.5B.) GPS extends survival to 30-40+ months (as the REGAL data implies), thus LTV estimate is: $260K (Y1) + $100K (Y2) + $100K (Y3) + $50K (Y4/Tail) = $510K Total LTV. $510K ÷ 3.5 years = $145K annual revenue per patient. The most interesting thing is new transplant ineligible patients in the U.S. (not including globally): There's only about 3,000 new CR2 and 6,000 new CR1 patients each year. If everyone mostly died in 8 months (like they do now), revenue would be small ($260K × 9,000 = $2.3B max). Because GPS keeps patients alive for 3-4 years, by Year 4, you aren't just treating the new patients. You are treating: 2026 survivors (Year 3 of dosing) 2027 survivors (Year 2 of dosing) 2028 new starts (Year 1 of dosing) This is what creates the 27,000 patient pool and the $4.0B+ annual revenue 4 x 3 to 5 Peak Sales (standard for general acquisitions in Bio) is 20B for example, and this is a breakthrough in oncology (where these types of assets are acquired for 6 to 8 times peak sales). The floor really is 10B, but I just said 6B because I'm a deep value investor and always assume worst case scenarios. You're right in that it is too low. The range is that broad because we ultimately don't know what the bidding war between strategics like ABBV, BMS, etc. will lead to, as we're just talking about GPS here for AML CR2 and CR1. We haven't even discussed SLS-009 (which will be bigger than GPS) for the Frontline, which is in Phase 2B, we haven't talked about the other indications from the WT1 targeting that is present in 20+ cancers, etc. Also, when I said 7.5X to 49X upside from current share prices (that was from when shares were about $3.70, so that 49X number would naturally drop as shares go up) In addition, I can also attach one image per reddit comment, so I attached one here that shows the overview for GPS annual sales globally that the acquirer would get. https://preview.redd.it/41mn1gxe1okg1.jpeg?width=1042&format=pjpg&auto=webp&s=aa53db604f6bbec856e9f78273fcc4bb16177035
Thank you for your comment. It's great to see you discussing the big picture with WT1 being expressed in almost 20+ cancers. WT1 is a universal target, which is why this drug has so much potential. But one small correction on the cellular mechanics of how it destroys the cell. The vaccine itself does not perforate the cancer cell. GPS is an immunotherapy. It's like a wanted poster where the immune system of the patient will recognize who to look that has WT1 expressed. When injected, it trains the patient's own immune system (specifically CD8+ Cytotoxic T-cells) to recognize the WT1 protein. Once trained, those T-cells are the ones that hunt down the cancer, lock onto the membrane, and release a protein called perforin to punch holes in the cancer cell and destroy it. But to answer your core questions: Does it work the same way for Ovarian cancer? Yes, WT1 is expressed in over 85% of ovarian cancers. SELLAS has actually already run Phase 1/2 trials in advanced ovarian cancer combining GPS with Keytruda/Opdivo. It successfully triggered that exact T-cell response and pushed median Overall Survival past 18 months in a very difficult to treat population. Does it work for any cancer expressing WT1? Exactly. Because the trained T-cells only look for the WT1 antigen, they don't care if the tumor is in the blood (AML), the lungs (Mesothelioma), or the ovaries. This is exactly why the National Cancer Institute ranked WT1 as the number 1 priority target for immunotherapy in the world." They specifically focused on AML and dominating AML with SLS-009 + GPS. Outside the lives saved and benefits for patients, strategic acquirers get excited about that given if they acquired SLS, that revenue stream would be protected for at least 7 years without any competition, the acquirer would have a monopoly in AML CR2 (not eligible for transplant), total dominance in CR1, and tons of penetration in the frontline with SLS-009. Strategic acquirers already in AML include ABBV, BMS, etc.
yea saw RKLB, LUNR, iren trending last year in wallstreet bets. i avoided them, definitely not touching that now. it's like buying palantir all over again ABBV looks wonderful in charts, too bad for the PE. seems risky i think. same with JNJ, i think i'm late and missed the bull run. rather buy more oil than that but thanks
J&J, ABBV I like for long term. RKLB, LUNR, iren are my more recent picks for the year. Not financial advice just me
Thank you, and there is no approved drug for AML CR2 (not eligible for transplant). At the BAT mOS range the predictive model predicts with 90% accuracy, GPS will/is increasing survival for these patients 3X to 4X. It will be the only approved drug that does this, and it beats standard of care in AML CR1 by at least 1.5X (this was Phase 2 data). Based on the Phase 3 AML CR2 (not eligible for transplant) data we are seeing clearly, it will do far beyond that 1.5X in CR1 with the unlimited dosing. The closest competitor is in Phase 1, for 5 to 8 years, there is no competitor in AML CR2 (not eligible for transplant), or anything that can achieve in AML CR1 that GPS can/is achieving. Annual Sales for GPS from AML CR2 (not eligible for transplant) and CR1 will be $4B+ globally, hence it will be acquired/bought-out by a strategic like ABBV, BMS, etc. There will be a bidding war, as it is/will be the most sought after oncology acquisition.
I’m so excited for Abbvie to buy my SLS shares and turn them into ABBV (my copium praying)
Thank you for your comment. This very well could happen. REGAL is such a massive catalyst and all that we're discussing in terms of results, buyout, etc. has been based on REGAL/GPS, but if SLS-009 results come out at that timeline, which they very well could, it will be a huge catalyst as well. For everyone's context that is new/reading this, here is an overview for what SLS-009 is: Phase 2 for SLS-009 proved that for patients that failed Venetoclax (ABBV's drug), where they typically survive 2.5 months afterwards, SLS-009 achieved an extended median OS of 8.9 months, which is a 3.5X improvement over standard of care. Venetoclax generates $2.5B+ in net revenue for ABBV, and SLS-009 protects that by making it effective for meaningfully longer. The combo also protects it from the patent cliff. The Current Standard in Frontline for AML: Aza/Ven is 14.7 median OS With SLS-009: Aza/Ven + SLS-009 likely would be 22 to 24 months median OS In TP-53 Mutated (High Risk): Aza/Ven is 5.3 months median OS Here, Aza/Ven + SLS-009 likely would be 15 to 16 months median OS They'll (ABBV) gain a minimum of $2B in revenue from acquiring SLS-009. Exciting for ABBV because after Phase 2B, it can be approved by 2027 given its fast track approval and orphan drug designation.
It's hard to predict a timeline, but it will be the most sought after oncology acquisition there is. Acquired most likely by relevant strategics like ABBV, BMS, etc. My recommendation would be to focus more on the buyout range, posted a comment here going over that in detail. But as an example, if REGAL FA results come out in Q3 2026, buyout may occur soon after with a closing date in Q4 2026/Q1 2027. My recommendation would be to not even focus on this, and just look the ranges (the other comment will help a lot here).
Thanks for your comment. I can expand on this but here is an overview in a concise way: GPS annual sales will be at least $4B and GPS + SLS-009 will be $6.5B to $8.5B.) GPS extends survival to 30-40+ months (as the REGAL data implies), thus LTV estimate is: $260K (Y1) + $100K (Y2) + $100K (Y3) + $50K (Y4/Tail) = $510K Total LTV. $510K ÷ 3.5 years = $145K annual revenue per patient. The most interesting thing is new transplant ineligible patients in the U.S. (not including globally): There's only about 3,000 new CR2 and 6,000 new CR1 patients each year. If everyone mostly died in 8 months (like they do now), revenue would be small ($260K × 9,000 = $2.3B max). Because GPS keeps patients alive for 3-4 years, by Year 4, you aren't just treating the new patients. You are treating: 2026 survivors (Year 3 of dosing) 2027 survivors (Year 2 of dosing) 2028 new starts (Year 1 of dosing) This is what creates the 27,000 patient pool and the $4.0B+ annual revenue 4 x 3 to 5 Peak Sales (standard for general acquisitions in Bio) is 20B for example, and this is a breakthrough in oncology. The floor really is 10B, but I just said 6B because I'm a deep value investor and always assume worst case scenarios. The range is that broad because we ultimately don't know what the bidding war between strategics like ABBV, BMS' etc. will lead to, as we're just talking about GPS here for AML CR2 and CR1. We haven't even discussed SLS-009 (which will be bigger than GPS) for the Frontline, which is in Phase 2B, we haven't talked about the other indications from the WT1 targeting that is present in 20+ cancers, etc.
There are indexes/ETFs so you don't have to choose. If you do choose, even Buffet/BRK (and me) underestimated how low UNH could go and bought too high. Honestly, I think USA crap shoot... I bought NVO then Trump made them lower prices, I bought UNH... then government decreased fees (which seems crazy since we can't allow them to fail). At this point my theory is, if you have any favorite drugs look up your favorites and invest in who makes them (for me it is cyclosporine and ABBV, for my wife it is Zepbound and LLY). At least that way you are emotionally invested and can cheer for your stock... I think of it like the old investment theory to invest in whoever you give the most of your money.
ABBV giving me a boner rn
Buffet bought back $25B in BRK stock, opened new positions in BMY, PFE, ABBV, MRK, and B, spent $B on Dominion's natural gas infrastructure, and added to existing positions. What in the world are you talking about? Just because he didn't spend all his cash doesn't mean he bought nothing.
ABBV ceo is missing for sure. Can't exclude the #1 maker of silicone implants.
Anyone know why ABBV (Abbvie pharma) is down so much? They beat on everything but margin I think. Guidance was good for 2026. Seems like a bit of an oversell?
Can’t believe my ABBV 210p went ITM
ABBV beats and dumps 2%. This is the dumbest timeline.
I've owned LLY for a few years now and am not selling or adding at this point. There would be other things ahead of it on the shopping list, but I'd be more interested in ABBV sub-$200.
PFE - Zoloft LLY - Prozac GSK - Paxil ABBV - Range of generic drugs in the same space
They likely tried already behind closed doors (offered 10B for MTSR, which is VERY inferior to VKTX and a lot further behind). However VKTX's management probably is asking for 25-40B in a buyout scenario (which is a huge premium on today's share price, but is what the company would be worth for VK2735). So it's a lot in the look of it. If you do a buyout for a 1200% premium, maybe the shareholders (who aren't necessarily knowledgeable in bio data) will not be happy. That's the only reason. You are right, I am extremely bullish on VKTX, see my last WSB DD on my profile for more info. I will also become extremely bullish towards the company that acquires or partners with VKTX and will buy a large position. This is because NVO/ABBV/MRK have a really good supply chain and marketing, they are just lacking a good product.
Personally I have significant long positions in TARS, NBIX and ABBV (although note I’ve been in these over a year and am not adding at these levels). I also hold SRPT and QURE. SRPT I also bought near book value when it was in the 13s QURE is a good example of biotech. Everything looked good and they were aligned with FDA on the trial design. Then last minute FDA reversed course and it’s now down 50% from my cost basis. But I sized accordingly given the historical control uncertainty so the damage isn’t too bad…
For me it’s Verizon. It’s not a super exciting stock and it’s not a stock that is going to see some double digit growth at any point. But that being said, it is trading at forward PE of 8, has a dividend yield of 7% at 60% payout ratio. It is a boring stock and I think a lot of people have been selling those types of stocks to chase the Palantirs and the Teslas around. Bought UPS recently for the same reason and have been up 30% in a couple months just based on valuation alone. Bought ABBV a while ago for the same reason and have been up 200% since, with a locked in dividend yield of 6%+.
When I first started investing, I was ignorantly looking at dividend yields instead of…anything else. I found ABBV at $82 with a 4 or 5% yield I think? Bought like 20 shares. Best uninformed decision in stocks I made.
That’s too far to extrapolate any reasonable data. While possible, it is not probable I would hold a trade 20 years. I have had ABBV since 2016. I held IEP for a decade. BRKB has stood the test of time. EQR based on the late great Sam Zell would have worked. The farther out we go the harder to predict based on current data. And from where I sit we are looking to take every advantage we to optimize a winning trade.
Fuck ABBV why the hell can’t you just be fucking green
I rarely hold a stock that long. Most people don’t hold a stock that long. We can’t prognosticate that far into the future. More importantly, what is your exit strategy? Without a strategy you are just a seal swimming amongst the sharks. Will you freak out if one stocks drops 50%? I already know the answer yet it begs the question. Are you doing any Fundamental Analysis? Technical Analysis? I don’t care for your picks, no disrespect. Your question is more complicated than you may think. I will play my part lest it be said I’m a curmudgeon. BRKB- buy the dips EQR- buy the dips CTRE COPY- buy the dips ABBV PSHZF CRSP- buy the dips until 2030 MKL This is what I have that I could reasonably conceive one may own ten years from now. I added CRSP for future potential rather than Fundamental or TA. Not my best work but what can you expect for free.
Odd. I opened an account with RH a view years ago and so far ABBV & XOM haven't emptied my account. I must be doing it wrong.
Traded GIS for VGT & sold HRB for ABBV. I am VERY happy I sold GIS and HRB. I also sold all my Gladstone stocks.
I like NET the best of this list. I’m seeing a whole lot of tech and the money is flowing into value as we revert to the means. The sectors hit the hardest this year have been oil and healthcare. I suspect they both outperform next year and I have been buying both. I am of the mindset you build a portfolio brick by brick. I said ABBV was a buy in 2016 and it’s a buy in 2026. I like BMY using a 25% trailing stop. Just as important is a strategy. Without a strategy you are just another bloke lost in the ocean of sharks. You should know your exit before you buy. Are you holding for decades? Buying the dips? Using a trailing stop? What allocation are you using? Savvy investors know the answers to these questions. *Be very wary of Reddit. Those that know what they are doing have little time to spend here, this you are left with the flotsam and jetsam.*
I've moved a portion of my investments to cash, or cash equivalents. My gut feeling is that the AI bandwagon is going to crash badly, and take the rest of the market with it. I'm investing in Healthcare stocks, like ABBV, COR, and also FPHAX since people don't stop getting sick. Also, consumer staples like WMT, CPB, COST (even though their P/E concerns me), and VDC.
I cannot wait to be free of this ABBV bullshit
ABBV AMAT CSU GD GOOG H IAG IPCO RY XOM VIDY Just kinda picked whatever looked okay. 33-33-33.
Sadly, I keep a list with sold prices, current price, and how much more i would have if i didn't sell. Yes. I am a masochist. And none of these are "kinda regret", they are full "please God, let me go back in time so i can prevent this". ABBV GOOGL IBM LEU MSFT MPLX PLTR VOO
What was your strike on the ABBV though?
Rolled it 23 times, screen froze, broker called to check if I was okay, and then, I found my Golden Parachute Superpower card! ABBV and the whole market bent to my will. WHEW! that was tense 😉
Doesn't sound correct. Say his earned income is $20K, he could (and should) be able to take up to $24,625 in long term cap gains, combined with any qualified dividends tax free. I harvested 200% gains in ABBV tax free and repurchased the stock the next day $3 cheaper(g).
I made out like a bandit selling ABBV stocks. Sounds everyone here just buys Mag7 and cries when the sector goes down.
Ive got these really shitty tickers clogging up my watchlist. ODNS ABBV NBIS Garbage
I spent some time on small cap biotech in early 2025 and concluded financial disclosures alone aren't enough to buy. Most have no earnings and are just looking for the next hot drug. It seems like you need to know their patent application pipeline - which is a lot of work and still very difficult to make value calls on unless you also have some idea of the patent universe for that class of chemicals. (Ph.D. in the space with a J.D. btw) Did buy a couple closer to mid caps - OGN (fortunately exited in early Oct but still see a value story) and VTRS. Also like the larger caps like AMGN and ABBV.
Good timing, about to sell out my shares of ABBV.
Hi, how are ya? I do all of my investing research and due diligence myself and my brokerage account is currently with Fidelity. Off the top of my head, CROX and ABBV are two stocks currently trading below their intrinsic value, based on their projected future free cash flow. There are many great investment web sites to learn from, including Seeking Alpha, The Motley Fool and Zacks. As far as the best investment companies, choose one that has the lowest fees involved, especially if you know how to do your own stock research. If you have more questions, feel free to ask. ☺️
Love to see a green day and my ABBV holdings down 2.5% fuck this company
I'm down like 20-30% on JD rn, but I got leaps so im chillin for now. UNH and ABBV have fucked me, so I guess JD didn't have too
ABBV’s earnings showed mixed but good results + raised its guidance for next year - The stock plummeted 4% afterwards and I bought it at a discount thinking its a good stock and that the market judges too swiftly and it must go up again. What do you guys think ?
> They only keep going up The market for the past decade, other than the Covid dip, has gone up. > the price of companies don't necessarily go down all that much Yes, if the overall market is going up, you don't see the value of high dividend stocks going down all that much. However . . Other than ABBV, the other stocks you mentioned have badly underperformed the index. And most pharm companies, even established ones, are gambles.
Not entirely sure how the whole: "it goes down when the dividends are paid" works since I invest on ETFS right now, Dividend & Growth etfs, but the price of companies don't necessarily go down all that much or if they do it might be for a week or so. Just basing this on stocks like JNJ, PG, PEP and ABBV. They only keep going up and they pay $1/share per dividend payout and their stocks don't necessarily go down one dollar for long. I do have reservations investing on anything thats on the red during their 5 year to MAX tenure graphs. Though if I'm incorrect I'd appreciate a clarification since that could help with deciding better company stocks.
ABBV 255 calls. 0.05 price for potential 5x. I know nothing about the company it’s just the cheapest option within range. Figured I’d share for other degens
I’ve been with Amazon since the first split and WWE since 13.00. Those are my two favorites with Kodak and ABBV
I usually buy ABBV for recessions.
I have been investing in the stock market for about 30 years and as you can imagine, I have accumulated many shares of stocks. I have mainly bought and held Dividend Aristocrats. Some of my big stock positions include ABBV(3700 shares), MCD(2550 shares) MO(7400 shares). I have begun selling covered calls on the stocks that I own. If my stocks were to be assigned, I would be subjected to hefty capital gains taxes. So, I have written covered calls that are out of the money with about 2-4 weeks time to expiration., to lower my risk of getting assigned. The premiums are anemic but my goal is to earn about $1,000 every two weeks on my positions. Am I expecting too much? Is my strategy correct?
ABBV for botox, EOLS for their competitor
NVO, LLY, ABBV, JNJ, ... There's a lot of BP left.
Some of my highest conviction positions I haven't seen mentioned: SYK - for surgical robotics & med tech ABBV - drug portfolio & discovery AMAT - semiconductor tech TSM - the best semiconductor fab CRWV - complex AI infrastructure
I'm Bear-curious on ABBV.
MRK ABBV UNH BMY. Make Health Win Again.
ABBV put holder. Exiting tomorrow.. rough go.
I sold ABBV at 190 because 🥭 kept on threatening pharma tariffs 🤡
ABBV literally finishing all over my face wtf
Goddamn ABBV chill the fuck out so I can sell my covered call at the top
Ran a little AI search last night when I was extremely crossfaded. Drug: Atorvastatin/Lipitor (PFE). US prescriptions: >115 million. Generic market share penetration: >90%. Drug: Lisinopril/Zestril (AZN). US prescriptions: >76 million. Generic market share penetration: 95% Drug: Levothyroxine/Synthroid (ABBV). US prescriptions: >80m. Generic market share penetration: ~60%
Drug: Atorvastatin/Lipitor (stock PFE). US prescriptions: >115 million. Generic market share penetration: >90%. Drug: Lisinopril/Zestril (AZN). US prescriptions: >76 million. Generic market share penetration: 95% Drug: Levothyroxine/Synthroid (ABBV). US prescriptions: >80m. Generic market share penetration: ~60% Read the fucking news. **BIG DICK MONEY INBOUND**
ABBV and CMI have been very good to me (and put money in my pocket)
ABBV crushing it lately
ABBV probably continues up tomorrow
Whoever told me to buy ABBV @ 110 a couple of years ago, thank you.
Why does ABBV go crazy in the premarket? Today especially? It seems like it goes up x% then draws back to a little bit above baseline every day
ALGN is a monopoly all competitors are cooked. It’s the reason I invested heavily into ABBV the moment they bought allergen. People will spend on their teeth. Plus they have a new state of the art scanner orthos will be forced to use. Also they were hit with 30% tariffs from Mexico, which will fade if not they are priced in. Nice catalyst. Easy 2-3x within 5 years it’s a gift. Hit it with size myself. It’s right at my average here. Gift of an entry.
Yeah, sure (sorry, this is a bit of a rambling rant, but gives you a little look inside my controlled chaos). The common theme is really simple, find wonderful companies and just keep buying them at decent value points and holding more and more over long periods of time. Before I started investing I tore through a bunch of books. I started following companies and engaging daily. Researching companies, jumping on earnings calls, looking over financials. I learned the foundational aspects of the art of valuation. The book that struck me the most was One up on Wall Street. We run into incredible companies all over in everyday life, keep your eyes open and you'll see them. That gives you a great spot to start your research. When you find good ones buy, get to know them better and if you're right buy more. Then buy some more and keep buying. And if you're wrong cut bait and move on quickly. IMO, reading and learning is lost on too many coming into investing today. If you don't want to learn and don't enjoy learning about the details of how a business functions you shouldn't be investing in equities. If you enjoy that as a hobby and want to use your time to do those activities, equity investing may be for you. This led me to buy Apple in 2008, Activision in 2009. Netflix and Google in 2011. Costco in 2012. Casey's General Store in 2012. Tesla in 2013 (although I'll still argue this was a stupid move by me as the financials were scary). NVDA in 2017. MELI in 2020. It also led me to others at great value points too like OKE and ABBV and NTDOY and 6016.T and KNSL. All solid, well run companies with a level of pricing power and some special sauce. And I don't really sell, if it's working I look for spots to add more. Also, I slowly built a cash allocation plan. I never invest just b/c I have money. I stack money until I high conviction idea. And I don't just buy once, I generally aim to build a position out over time, getting to know a company better and better and building knowledge and conviction...or not and then I cut bait. That may lead to long periods where I'm sitting on cash equivalents (like SGOV and some select Munis and high quality Bonds right now). But then when I see value I generally go crazy. Example, in 2018/19 I was building a few positions (like NVDA) but largely building cash as I didn't have any great ideas. I was still buying small tranches of my favorite companies, but in small increments (I'll be a net buyer of equities until I die). Then when 2020 hit valuations were massively attractive so I went crazy. I made about 100 buys between Feb and August. Did the same in April of this year...over a 2 week period I deployed a massive pile of cash. When the market provides attractive valuations, I always have cash ready to go. I'll never deploy 100% of my cash and new money always goes immediately to cash holdings. Options -- My thoughts are simple...if valuations are stretched and you're ok moving on from some shares, sell covered calls. If valuations are low and you would like to take on some shares at specific price points, sell puts. Around 2013 I picked up Options as a Strategic Investment (the options bible IMO). I don't necessarily aim to TRADE, but to use options as part of my long term buy and hold strategy. That leads to me SELLING a ton of options, but buying very very few. In April of this year I sold a ton of puts at prices I wanted to add shares. I'm generally very conservative here so the only equity I took on was HIMS in the 25-30 range (below my fair value range by a fair %). The others just added cash to the cash pile. Google is a good example. I was selling puts in the 120-135 range, but I was also buying a little in the 150-170 range. Recently I've been selling a lot of HIMS (overvalued from my 33-37 fair value range), NVDA (I never rebalance to rebalance but this position is extreme and above my 130-142 fair value range) and AAPL (above my 180ish fair value range) covered calls. I've also been selling CRM puts in a conservative 205-220 range (just above my 197 bear case and below my 225-250 fair value range). I don't recommend options for most, but if you really have a good feel for valuations you can use them strategically to get in and out of positions and drive additional cash to invest.
I have to agree that having SCHG and VOO is pointless after reading my own comment about growth over 5 years. Makes no sense. I'd consider selling SCHG to take more concentrated positions in MSFT, NVDA, UNH, ABBV, and GOOG but if we're talking ASTS, PLTR, and HOOD growth type stocks then I don't have the dry powder for that. I don't even know which companies have that potential right now. Either way, I was looking at the fees, which are on top of commission, and it's not worth it to get a managed fund. Some fund managers absolutely kill it, but they're not hanging around my price point.
60% ABT and 40% ABBV. Growth and sweet dividend hard to beat. Neither company is going anywhere.
That's incredible! We need more days like this! While tech is being decimated... other sectors are attracting all the money! Berkshire, AZN, MRK, ... TJX, DOW, UL, ABBV, ...
I bought 100 shares of GILD and ABBV to write covered calls at the top
I bought 100 shares of GILD and ABBV to write covered calls at the top
Oral data due imminently, fireworks to come, could see plus or minus $25. My bet is plus given the overwhelming positive data released in both SQ and oral. Remember it’s the same compound. Just a matter of time before PFE, MRK or ABBV takes them out imo.
Doesn’t $ABBV grow more than anyone else?
Somehow lost 30k on AMD calls before big run up. But really hit with Boeing, ABBV and recently Apple. So need to push out some gains until next year while still participating.
3% diagnosed. probably more like 7-10% with undiagnosed, and only about 50% of diagnosed people are still untreated. even just 15 million people is a huge patient population. also ABBV has an insane amount of money to burn on ads and losing Humira means they're pumping all the old budget at the replacements including rizi
RSG, ABBV, WMT Fund-wise BRW (Saba Capital Income & Opportunities Fund) is an interesting CEF that has done pretty well since Saba Capital took it over and changed the fund entirely in 2021. It lost 4% in 2022 when the market was tanking and lost comparatively less than the market when the market was tanking in 2025, yet has also done pretty well when the market has.
Oh so now that ABBV had great earnings the market wants to tank. Fucks sake
Even my ABBV will hit 200 before my GOOGL…
Imagine buying any other healthcare other than ABBV
ABBV is my only healthcare only left, dont let me down you fucks..
I own UNH, PFE, and ABBV so it probably makes up a good chunk of my taxable account. I'm not that worried about it though unless the U.S. moved to a Universal Healthcare System. In which case, I would gladly take the loss.
If this amount of yours in a tax-privileged account (IRA, 401k), you can move the funds in a 3-tier layout: 33% bonds, 34% divident-paying safe stocks (ABBV, etc) and 33% in etfs (VOO, SCHD, VTI).
The fact that $VKTX can offer potential oral and monthly maintenance after SC with the same molecule is not to be underestimated. Even $LLy does not have that. It is uncertain how people will react when switching from TP to orfoglipron.. large pharma eyes on that as almost everyone there is talking about need for solutions for long-term adherence beyond 1-2 years. Listen to $ABBV $PFE and others. Don’t believe $NVO semaglutide is competitive with that Viking only needs to show that small dose oral has any activity in phase 2 in a few weeks
SIGH i have been saying since premarket…why choose to turn a deaf ear? good news is we will stop the dump soon FOR TODAY, ur only chance to cut losses. we will continue to dump over the few weeks. in the meantime the index will go up a little as we readjust portfolio if u prefer to hold stocks buy NKE PG CPB KHC CAG JNJ MRK XHB ABBV BRKB UNH